On the probability that a novel variant is a disease-causing mutation.

Area of Science:

• Genetics
• Population Genetics
• Bioinformatics

Background:

• Identifying disease-causing mutations relies on finding novel variants in patients absent in controls.
• Current methods lack a statistical framework to assess the likelihood of a novel variant being neutral.
• Single nucleotide polymorphisms (SNPs) are common genetic variations that require careful interpretation.

Purpose of the Study:

• To develop a population genetics-based method for calculating a P-value for mutation detection efforts.
• To provide a statistical tool for assessing the probability that a novel SNP is a neutral variant.
• To account for multiple testing in variant identification for case-control studies.

Main Methods:

• Developed a population genetics-based statistical method to calculate P-values.
• The method accommodates various patient genetic states: heterozygous, homozygous, with/without inbreeding, and compound heterozygotes.
• Calculates the probability of detecting neutral variants at different frequencies between patient and control groups based on sequence length.

Main Results:

• The developed method provides a P-value for mutation detection efforts.
• It can assess the probability of a novel SNP being neutral across different patient genetic scenarios.
• For 10 kb resequencing, the probability of a neutral variant appearing in a patient but not 50 controls is approximately 15%.

Conclusions:

• A novel variant found in a patient but not in controls is weak evidence of disease association on its own.
• The developed population genetics method offers a robust statistical framework for interpreting genetic variants.
• This approach is essential for accurate variant analysis in genetic association studies and personalized medicine.